ATE105478T1 - Verwendung eines derivates des 1,3,7trimethylxanthins zur behandlung von gedaechtnisstoerungen, intellektuellen stoerungen im alter, und bei der alzheimerkrankheit. - Google Patents

Verwendung eines derivates des 1,3,7trimethylxanthins zur behandlung von gedaechtnisstoerungen, intellektuellen stoerungen im alter, und bei der alzheimerkrankheit.

Info

Publication number
ATE105478T1
ATE105478T1 AT9090402558T AT90402558T ATE105478T1 AT E105478 T1 ATE105478 T1 AT E105478T1 AT 9090402558 T AT9090402558 T AT 9090402558T AT 90402558 T AT90402558 T AT 90402558T AT E105478 T1 ATE105478 T1 AT E105478T1
Authority
AT
Austria
Prior art keywords
alzheimer
disease
treatment
aging
derivative
Prior art date
Application number
AT9090402558T
Other languages
English (en)
Inventor
Annie Kamoun
Elisabeth Mocaer
Gilbert Regnier
Claude Guillonneau
Jacques Duhault
Original Assignee
Adir
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Adir filed Critical Adir
Application granted granted Critical
Publication of ATE105478T1 publication Critical patent/ATE105478T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

Landscapes

  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
AT9090402558T 1990-08-10 1990-09-17 Verwendung eines derivates des 1,3,7trimethylxanthins zur behandlung von gedaechtnisstoerungen, intellektuellen stoerungen im alter, und bei der alzheimerkrankheit. ATE105478T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FR9010235A FR2665636B1 (fr) 1990-08-10 1990-08-10 Utilisation d'un derive de la trimethyl-1,3,7 xanthine pour le traitement des troubles de la memoire, des troubles intellectuels de la senescence et de la maladie d'alzheimer.

Publications (1)

Publication Number Publication Date
ATE105478T1 true ATE105478T1 (de) 1994-05-15

Family

ID=9399600

Family Applications (1)

Application Number Title Priority Date Filing Date
AT9090402558T ATE105478T1 (de) 1990-08-10 1990-09-17 Verwendung eines derivates des 1,3,7trimethylxanthins zur behandlung von gedaechtnisstoerungen, intellektuellen stoerungen im alter, und bei der alzheimerkrankheit.

Country Status (15)

Country Link
US (1) US5173491A (de)
EP (1) EP0470317B1 (de)
JP (1) JPH0647539B2 (de)
AT (1) ATE105478T1 (de)
AU (1) AU631679B2 (de)
CA (1) CA2026118C (de)
DE (1) DE69008853T2 (de)
DK (1) DK0470317T3 (de)
ES (1) ES2056415T3 (de)
FR (1) FR2665636B1 (de)
HK (1) HK56997A (de)
IE (1) IE65158B1 (de)
NZ (1) NZ235389A (de)
OA (1) OA09464A (de)
ZA (1) ZA907739B (de)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2093403C (en) * 1992-04-08 1999-08-10 Fumio Suzuki Therapeutic agent for parkinson's disease
US5484920A (en) * 1992-04-08 1996-01-16 Kyowa Hakko Kogyo Co., Ltd. Therapeutic agent for Parkinson's disease
FR2692784B1 (fr) * 1992-06-24 1995-06-30 Pf Medicament Utilisation de la guanosine, de ses precurseurs et ses derives pour la fabrication de medicaments destines a traiter les deficits fonctionnels cerebraux.
JP2613355B2 (ja) * 1992-09-28 1997-05-28 協和醗酵工業株式会社 パーキンソン氏病治療剤
ATE325610T1 (de) * 1997-09-05 2006-06-15 Kyowa Hakko Kogyo Kk Xanthinderivative zur behandlung von hirnischämie
WO2001079837A1 (en) * 2000-04-12 2001-10-25 Repligen Corporation Methylxanthines in the diagnosis and treatment of autistic disorder
AR039385A1 (es) * 2002-04-19 2005-02-16 Astrazeneca Ab Derivados de tioxantina como inhibidores de la mieloperoxidasa
SE0302756D0 (sv) * 2003-10-17 2003-10-17 Astrazeneca Ab Novel Compounds
EP1709966A4 (de) * 2003-12-09 2009-04-29 Prophylaktisches und/oder therapeutisches mittel für höhere gehirnfunktionsstörungen
SE0402591D0 (sv) * 2004-10-25 2004-10-25 Astrazeneca Ab Novel use
MY140748A (en) * 2004-12-06 2010-01-15 Astrazeneca Ab Novel pyrrolo [3,2-d] pyrimidin-4-one derivatives and their use in therapy
TW200804383A (en) * 2006-06-05 2008-01-16 Astrazeneca Ab New compounds

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2558162B1 (fr) * 1984-01-17 1986-04-25 Adir Nouveaux derives de la xanthine, leurs procedes de preparation et les compositions pharmaceutiques les renfermant
US4755517A (en) * 1986-07-31 1988-07-05 Warner-Lambert Company Derivatives of xanthine, pharmaceutical compositions and methods of use therefor
GB8621870D0 (en) * 1986-09-11 1986-10-15 Beecham Group Plc Active compounds
US4783530A (en) * 1986-11-13 1988-11-08 Marion Laboratories, Inc. 8-arylxanthines
GB8819494D0 (en) * 1988-08-16 1988-09-21 Ucb Sa Use of 2-amino-4-morpholino-6-propyl-1 3 5-triazines for preparation of psychotropic medicaments

Also Published As

Publication number Publication date
JPH0495029A (ja) 1992-03-27
CA2026118C (fr) 1998-07-14
AU631679B2 (en) 1992-12-03
US5173491A (en) 1992-12-22
FR2665636A1 (fr) 1992-02-14
JPH0647539B2 (ja) 1994-06-22
DE69008853D1 (de) 1994-06-16
EP0470317A1 (de) 1992-02-12
EP0470317B1 (de) 1994-05-11
HK56997A (en) 1997-05-09
OA09464A (fr) 1992-11-15
DE69008853T2 (de) 1994-10-13
DK0470317T3 (da) 1994-09-19
ES2056415T3 (es) 1994-10-01
FR2665636B1 (fr) 1994-10-07
CA2026118A1 (fr) 1992-02-11
ZA907739B (en) 1991-07-31
IE65158B1 (en) 1995-10-04
AU6322890A (en) 1992-05-14
NZ235389A (en) 1991-12-23

Similar Documents

Publication Publication Date Title
DK549189D0 (da) Galanthamin-analoge samt anvendelse af disse til fremstilling af laegemidler til behandling af alzheimer's syge
DE69012591T2 (de) Verwendung von Nikotin zur Herstellung eines Kit zur Behandlung von Krankheitszuständen, die auf eine Nikotinbehandlung ansprechen.
ATE105478T1 (de) Verwendung eines derivates des 1,3,7trimethylxanthins zur behandlung von gedaechtnisstoerungen, intellektuellen stoerungen im alter, und bei der alzheimerkrankheit.
DE3684190D1 (de) Verwendung von tetrahydrobiopterinen zur herstellung eines medikaments zur behandlung von kinderautismus.
NO304071B1 (no) Heterocyklisk-cykliske amin-derivater
ATE116312T1 (de) Antimigräne alkoxypyrimidinderivate.
DE69121561T2 (de) Verwendung von 3-guanidinopropionsäure zur herstellung eines medikaments zur behandlung und prävention von fettsucht
DE68901511D1 (de) Verwendung von 2-amino-4-morpholino-6-propyl-1,3,5-triazin zur herstellung eines medikaments zur behandlung kognitiver und mentaler erkrankungen.
EE03953B1 (et) 2-fenüül-1,2-bensisoseleenasool-3(2H)-ooni kasutamine farmatseutilise preparaadi valmistamisel Alzheimeri tõve raviks
DE59307982D1 (de) Verwendung von NADH und NADPH zur Herstellung eines Arzneimittels zur Behandlung von Morbus Alzheimer
ATE89728T1 (de) Verwendung von dihydroergotamin und seinen salzen zur lokalen behandlung trophischer stoerungen.
EP0345247A3 (de) Verwendung von monosubstituierten selenorganischen Verbindungen zur Herstellung eines Arzneimittels sowie daraus hergestelltes Arzneimittel und Verfahren zu seiner Herstellung
DE59003534D1 (de) Verfahren zur Herstellung von Triethylendiamin und Piperazin.
ATE294584T1 (de) Verwendung von desoxypeganin zur behandlung von alzheimerischer demenz
IL97054A0 (en) Pharmaceutical compositions comprising buspirones for the treatment of sleep apneas
DE69621786T2 (de) Aminotetralinderivat zur behandlung von herzkreislauferkrankung
ES2009689A6 (es) Procedimiento para preparar derivados de 3-piperidina-carbaldehido-oxima.
DE69300037T2 (de) Verwendung von Bucillamin zur Herstellung eines Arzneimittels zur Behandlung von Cystinuria.
DK0538690T3 (da) Arylquinolyl-substituerede 1,4-dihydropyridin-dicarboxylsyrederivater, fremgangsmåde til deres fremstilling af deres anvendelse i lægemidler
DE59107405D1 (de) Ein Imidazobenzodiazepin zur Behandlung von Schlafstörungen
DE68914886D1 (de) Mittel zur Behandlung von Raynaud's Krankheit.